抗体药物偶联物治疗HER-2阳性乳腺癌的机制与研究进展

Mechanism and research progress of antibody-drug conjugate in the treatment of HER-2 positive breast cancer

人表皮生长因子受体2(HER-2)阳性乳腺癌的诊治一直是乳腺癌领域的研究热点。单克隆抗体类药物和小分子酪氨酸激酶抑制剂的接连问世极大地改善了HER-2阳性乳腺癌患者的预后。然而,在极佳疗效的背后,靶向药物同样面临着多重耐药现象及心脏毒性等亟待解决的重大难题。近年来,随着HER-2阳性乳腺癌进入“精准分类,精确分层”的时代,抗体药物偶联物(ADC)成为肿瘤患者精准化治疗的热点领域之一。ADC通过特定的连接头将靶标特异性的单克隆抗体与高杀伤性的细胞毒性药物偶联起来,对肿瘤细胞具有高度特异性杀伤作用。本文就ADC的作用机制及其在HER-2阳性乳腺癌中的研究进展作一综述。

The diagnosis and treatment of human epidermal growth factor receptor 2(HER-2)-positive breast cancer has always been a research hotspot in the field of breast cancer.The successive advent of monoclonal antibody drugs and small molecule tyrosine kinase inhibitors has greatly improved the prognosis of patients with HER-2 positive breast cancer.However,behind the excellent efficacy,targeted drugs are also facing major problems such as multi-drug resistance and cardiotoxicity.In recent years,as HER-2-positive breast cancer has entered the era of"precise classification and precise stratification",antibody-drug conjugate(ADC)has become one of the hot areas of precise treatment for cancer patients.ADC binds target-specific monoclonal antibodies to highly cytotoxic drugs through a specific linker,which has a highly specific killing effect on tumor cells.This article reviews the mechanism of ADC and its research progress in HER-2 positive breast cancer.